Oliver Sartor, MD, discusses how 68galliumPSMA-11 PET-CT imaging is utilized in prostate cancer management, addressing its clinical applications, availability challenges, role in treatment eligibility assessment, unmet needs, and patient case considerations for metastatic castration-resistant prostate cancer (mCRPC).
EP. 1: Patient Profile 1: A 70-Year-Old Man With PSMA-Positive mCRPC
October 15th 2024Oliver Sartor, MD, discusses how a 70-year-old man with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) represents a typical candidate for PSMA-targeted imaging and potential radioligand therapy, considering factors such as disease progression, previous treatments, and overall health status in tailoring management strategies.
EP. 3: Utilization of 68Gallium PSMA-11 in Clinical Practice
October 29th 2024The panelist discusses how the limited availability of 68gallium PSMA-11 gozetotide in clinical practice poses challenges and suggests potential strategies to increase accessibility, such as expanding production facilities, improving distribution networks, and exploring alternative radiotracers with longer half-lives.
EP. 4: Confirming Eligibility for Lutetium Therapy
November 5th 2024Oliver Sartor, MD, discusses how 68gallium PSMA-11 PET is indeed the preferred imaging modality for confirming eligibility for lutetium therapy, but when unavailable, alternative options such as F-18 PSMA PET, conventional bone scintigraphy, or CT/MRI may be considered, albeit with potential limitations in sensitivity and specificity.